Table 2. Univariate and multivariate analysis of prognostic factors in patients with ENKTL.
| Progression-free survival | Overall survival | |||||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||
| P-value | HR (95% CI) | p-value | P-value | HR (95% CI) | p-value | |
| Age > 60 years | 0.515 | — | — | 0.605 | — | — |
| Male sex | 0.607 | — | — | 0.504 | — | — |
| Elevated LDH level | 0.034 | 2.093 (0.780-5.614) | 0.142 | 0.045 | 0.891 (0.354-2.239) | 0.805 |
| ECOG PS above grade 2 | 0.047 | 0.804 (0.274-2.354) | 0.690 | 0.021 | 0.693 (0.208-2.307) | 0.550 |
| High SUVmax on PET/CT | 0.002 | 1.796 (0.881-3.663) | 0.107 | 0.007 | 0.614 (0.257-1.468) | 0.273 |
| High MTV status | <0.001 | 3.810 (1.751-8.293) | 0.001 | <0.001 | 2.473 (1.492-6.162) | 0.032 |
| Tumor necrosis | <0.001 | 3.015 (1.210-7.508) | 0.018 | <0.001 | 3.482 (1.365-8.888) | 0.009 |
| Local tumor invasiveness | <0.001 | 2.962 (1.347-6.513) | 0.007 | <0.001 | 2.484 (1.067-5.787) | 0.035 |
| Complete resection | 0.009 | 0.299 (0.108-0.829) | 0.020 | 0.002 | 0.305 (0.106-0.879) | 0.028 |
| Regional LN involvement | <0.001 | 5.728 (2.428-13.513) | <0.001 | <0.001 | 5.037 (2.284-11.203) | <0.001 |
| B symptoms | 0.017 | 0.408 (0.148-1.122) | 0.082 | 0.018 | 1.301 (0.417-4.057) | 0.650 |
| High KPI score | 0.012 | 0.685 (0.187-2.510) | 0.568 | 0.033 | 0.407 (0.102-1.620) | 0.202 |
| High CAR | <0.001 | 2.038 (0.849-4.881) | 0.111 | <0.001 | 1.461 (0.591-3.611) | 0.411 |
| High GPS | 0.009 | 0.853 (0.393-1.848) | 0.686 | 0.007 | 1.758 (0.792-3.902) | 0.165 |
LDH, lactate dehydrogenase; ECOG, Eastern Cooperattive Group; PS, performance status; EN, extranodal; SUVmax, maximum standard uptake value; PET/CT, positron emission tomography/computed tomography; MTV, metabolic tumor volume; LN, lymph node; KPI, Korean Prognostic Index; CAR, C-reactive protein/albumin ratio; GPS, Glasgow prognostic score.